Jørgen Vestbo Selected Research

fluticasone furoate

1/2020	Real-World Data and Randomised Controlled Trials: The Salford Lung Study.
1/2020	Impact of socioeconomic status on participation and outcomes in the Salford Lung Studies.
2/2019	Impact of pre-enrolment medication use on clinical outcomes in SUMMIT.
1/2019	Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups.
1/2018	Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study.
1/2018	β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT.
1/2018	Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease.
1/2018	Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk.
11/2017	Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.
10/2017	Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jørgen Vestbo Research Topics

Disease

197	Chronic Obstructive Pulmonary Disease (COPD) 10/2022 - 08/2002
19	Emphysema 01/2021 - 12/2009
16	Asthma (Bronchial Asthma) 10/2022 - 09/2004
16	Inflammation (Inflammations) 10/2021 - 09/2004
15	Pneumonia (Pneumonitis) 01/2021 - 02/2007
11	Cardiovascular Diseases (Cardiovascular Disease) 04/2019 - 03/2011
7	Dyspnea (Shortness of Breath) 01/2022 - 09/2005
7	Obstructive Lung Diseases (Obstructive Lung Disease) 02/2019 - 03/2011
5	Respiratory Insufficiency (Respiratory Failure) 10/2020 - 01/2013
5	Fatigue 12/2016 - 01/2011
4	Disease Progression 01/2022 - 08/2008
3	Lung Diseases (Lung Disease) 01/2021 - 09/2005
3	Myocardial Infarction 10/2017 - 11/2012
2	Obesity 01/2021 - 10/2016
2	COVID-19 12/2020 - 10/2020
2	Fibrosis (Cirrhosis) 07/2020 - 10/2011
2	Heart Failure 01/2017 - 11/2012
2	Gastroesophageal Reflux (GERD) 09/2015 - 01/2015
2	Chronic Disease (Chronic Diseases) 08/2015 - 08/2012
2	Lung Neoplasms (Lung Cancer) 05/2015 - 11/2012
2	Pulmonary Embolism 11/2012 - 09/2005
1	Lung Injury 01/2021
1	HIV Infections (HIV Infection) 01/2021
1	Pathologic Processes 11/2020
1	Bone Resorption 10/2020
1	Apnea 01/2020

Drug/Important Bio-Agent (IBA)

57	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2009
47	GoldIBA 11/2020 - 08/2002
44	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 01/2003
22	Bronchodilator Agents (Bronchodilators)IBA 01/2022 - 01/2003
20	fluticasone furoate FDA Link 01/2020 - 05/2013
20	vilanterolIBA 01/2020 - 05/2013
11	Proteins (Proteins, Gene)FDA Link 04/2019 - 01/2009
11	Salmeterol Xinafoate (Serevent)FDA Link 01/2018 - 02/2003
10	Fluticasone (Cutivate)FDA LinkGeneric 01/2020 - 02/2003
10	C-Reactive ProteinIBA 01/2018 - 02/2007
9	Fibrinogen (Factor I)FDA Link 11/2019 - 01/2012
8	Pharmaceutical PreparationsIBA 01/2021 - 09/2009
8	Oxygen (Dioxygen)IBA 10/2020 - 09/2003
7	Anti-Bacterial Agents (Antibiotics)IBA 06/2021 - 08/2002
7	Interleukin-6 (Interleukin 6)IBA 01/2021 - 01/2009
7	Formoterol Fumarate (Oxis)FDA Link 01/2018 - 01/2013
6	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 01/2021 - 12/2012
6	Muscarinic AntagonistsIBA 01/2020 - 10/2010
6	Beclomethasone (Beclometasone)FDA Link 01/2018 - 01/2013
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 01/2009
5	Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric 01/2018 - 01/2016
5	SteroidsIBA 01/2018 - 03/2007
4	SmokeIBA 01/2021 - 12/2009
4	Interleukin-8 (Interleukin 8)IBA 01/2018 - 05/2009
4	Tiotropium Bromide (Spiriva)FDA Link 05/2017 - 10/2010
3	GasesIBA 01/2022 - 03/2014
3	CytokinesIBA 01/2021 - 01/2021
3	EnzymesIBA 01/2021 - 09/2004
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2020 - 09/2011
3	prednylidene (Pred)IBA 01/2018 - 08/2014
3	indacaterolIBA 01/2018 - 01/2016
3	Vitamin D FDA LinkGeneric 08/2014 - 10/2013
2	Immunoglobulin E (IgE)IBA 10/2022 - 02/2006
2	GlucocorticoidsIBA 01/2022 - 01/2016
2	Dihydrotachysterol (AT 10)IBA 07/2021 - 01/2017
2	InterleukinsIBA 01/2021 - 08/2014
2	FibrinIBA 11/2020 - 11/2019
2	von Willebrand FactorIBA 07/2020 - 01/2020
2	ElastinIBA 11/2019 - 01/2016
2	Indicators and Reagents (Reagents)IBA 01/2018 - 08/2002
2	CollagenIBA 12/2017 - 10/2016
2	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 11/2017 - 09/2014
2	Prednisolone (Predate)FDA LinkGeneric 08/2017 - 01/2017
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 06/2016 - 01/2015
2	CalciumIBA 01/2016 - 08/2014
2	AcidsIBA 09/2015 - 01/2015
2	Biological ProductsIBA 11/2014 - 03/2011
1	Omalizumab (Xolair)FDA Link 10/2022
1	Immunoglobulins (Immunoglobulin)IBA 10/2022
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2022
1	ferric oxide (iron oxide)IBA 10/2021
1	Lipopolysaccharide ReceptorsIBA 01/2021
1	Interferon-gamma (Interferon, gamma)IBA 01/2021
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2021
1	insulin receptor-related receptor (IRR)IBA 01/2021
1	Interleukin-1beta (Interleukin 1 beta)IBA 01/2021
1	Collagen Type VIIBA 07/2020
1	Hormones (Hormone)IBA 07/2020
1	Peptides (Polypeptides)IBA 07/2020
1	endotrophinIBA 07/2020
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2020
1	LipidsIBA 01/2020

Therapy/Procedure

43	Therapeutics 07/2021 - 11/2004
6	Nebulizers and Vaporizers (Inhaler) 01/2019 - 01/2013
3	Noninvasive Ventilation 11/2014 - 01/2013
2	Precision Medicine 01/2021 - 02/2016
2	Drug Therapy (Chemotherapy) 01/2021 - 08/2008
2	Critical Care (Surgical Intensive Care) 12/2016 - 01/2013
2	Dry Powder Inhalers 12/2015 - 09/2015
2	Patient Readmission 08/2005 - 01/2003
1	Aftercare (After-Treatment) 01/2022
1	Activities of Daily Living (ADL) 01/2022
1	Patient Care Bundles 07/2021
1	Length of Stay 05/2021